Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adma Biologics Inc. (ADMA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Adma Biologics Inc. ever had a stock split?
Adma Biologics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Adam S. Grossman CEO | NASDAQ (NMS) Exchange | 000899104 CUSIP |
| US Country | 685 Employees | - Last Dividend | - Last Split | 17 Oct 2013 IPO Date |
Overview
ADMA Biologics, Inc. is a biopharmaceutical entity deeply engaged in the realm of specialty plasma-derived biologics targeting the treatment and management of immune deficiencies and infectious diseases on both domestic and global fronts. With its incorporation in 2004 and headquarters nestled in Ramsey, New Jersey, ADMA Biologics has dedicated itself to the innovation, production, and distribution of transformative therapies. By operating source plasma collection facilities and relying on a network of independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers, ADMA Biologics ensures the availability of its critical healthcare solutions across various regions.
Products and Services
ADMA Biologics’ portfolio is a testament to its commitment to addressing unmet medical needs, primarily focusing on primary humoral immunodeficiency (PI) and prevention against Hepatitis B exposure. Below is a detailed examination of its key products:
- BIVIGAM
An intravenous immune globulin (IVIG) therapy, BIVIGAM is meticulously designed for patients grappling with primary humoral immunodeficiency (PI). This product epitomizes ADMA Biologics’ dedication to enhancing the lives of patients by offering a solution to boost their immune system.
- ASCENIV
ASCENIV, another IVIG product in ADMA’s toolkit, targets the same patient population affected by PI. Its introduction into the market signifies the company’s relentless pursuit of innovation and improvement in treatment options for those with immune deficiencies.
- Nabi-HB
Focused on the prevention of acute exposure to blood containing Hepatitis B surface antigen among other risk exposures to Hepatitis B, Nabi-HB is a testament to ADMA Biologics’ commitment to broadening its impact beyond immune deficiencies to addressing infectious diseases.
In addition to these market-ready solutions, ADMA Biologics is actively developing a promising pipeline of plasma-derived therapeutics aimed at pioneering methods of treatment and prevention for S. pneumonia infection, further underscoring its pivotal role in advancing healthcare through innovation.
Contact Information
